AstraZeneca treatment for hypereosinophilic syndrome granted orphan status

Writer, Stock Market Wire
Wednesday, February 6, 2019 - 08:19

AstraZeneca said US regulators had granted orphan drug status for its treatment for hypereosinophilic syndrome, a rare condition that can damage organs in the body.

The Food and Drug Administration grants orphan status to medicines intended for the treatment of rare diseases or disorders that affect fewer than 200,000 people in the US.

A phase II clinical trial of the treatment, Fasenra, had been conducted by the US National Institutes of Health in collaboration with AstraZeneca.

The results were expected to be published later in 2019.

At 8:19am: (LON:AZN) AstraZeneca PLC share price was -46p at 5663p


Related content

AstraZeneca's oral diabetes treatment gets European regulatory approval

AstraZeneca said European regulators had approved its supplementary oral treatment for overweight type-one diabetes patients, whose glucose levels were not adequately controlled with insulin alone....

Mon, 25/03/2019 - 07:23


Smiths Group and Pharmaceutical Stocks

“Having enjoyed a strong finish on Thursday amid a big slide in sterling, the FTSE 100 is modestly lower on Friday as news that the...

Fri, 22/03/2019 - 10:04


Astrazeneca's lung disease treatment granted orphan drug status in US

Astrazeneca said its potential new treatment for lung disease had been granted orphan drug designation by the US Food and Drug Administration.

The company's 'potential'...

Mon, 18/03/2019 - 07:42


Broker Forecast - Goldman Sachs issues a broker note on AstraZeneca PLC

Goldman Sachs today reaffirms its sell investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 5000p (from 4080p).

Broker Forecasts data provided...

Tue, 12/03/2019 - 13:10


AstraZeneca, Merck breast cancer treatment gets EU regulatory nod

AstraZeneca and Merck said they had a received a positive opinion from EU regulators on a treatment for breast cancer.

The Committee for Medicinal Products...

Fri, 01/03/2019 - 15:11